The biotech sector has been a strong performer in 2019 after becoming quite oversold during the plunge in the high-beta parts of the market in the fourth quarter of 2018. Helping the sector recover and get off to a raucous start to the New Year were large buyouts of Celgene Corp(CELG) and Loxo Oncology Inc(LOXO) to start 2019, both with significan…
{iframe}https://realmoney.thestreet.com/investing/stocks/roche-deal-for-spark-therapeutics-shows-biotech-merger-spark-hasnt-died-14876361{/iframe}